[R01] Efficacy of targeting GAPM3 to block acute and chronic Toxoplasma gondii infections
Ente: National Institute of Allergy and Infectious Diseases
Scadenza: 2031-05-31
Importo max: $463,290
Paese: US
Descrizione
PROJECT SUMMARY
Toxoplasma gondii infects an estimated 25–30% of the human population and poses a major public
health challenge, particularly in immunocompromised individuals and during pregnancy. Current treatments are
limited by toxicity, incomplete efficacy, and an inability to eliminate chronic
Settori: National Institute of Allergy and Infectious Diseases
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.